Atum, a Newark biotechnology company, saw business drop off as the pandemic hit. After a pivot to making synthetic coronavirus proteins, orders and production soared.
https://t.co/aLRTDOLhLR
This Bay Area company thought it might not survive. Then it started making coronavirus spike proteins